Dauricine

Research use only, not for human use.

Dauricine has pulmonary toxicity, can produce pulmonary injury in CD-1 mice by the metabolism of Dauricine mediated by CYP3A.

Dauricine has pulmonary toxicity, can produce pulmonary injury in CD-1 mice by the metabolism of Dauricine mediated by CYP3A. Dauricinec can pass the blood-brain barrier, and that P-glycoprotein has an important role in the transportation of Dauricine across the blood-brain barrier. Dauricine may has anti-tumor effect, can inhibit tumor cells in urinary system and colon cancer cell proliferation, invasion; induce cell apoptosis by suppressing NF-kappaB activity and the expression profile of its downstream genes.

Apoptosis Analysis Cell Line:HCT 116 Concentration:5, 10, 20 μM Incubation Time:36 h Result:Showed he percentages of apoptotic rate of 7.8% to 14.4%, 19.8%, and 29.7% at 5, 10, and20 μM.Increased the accumulation of cleavage PARP and caspase3.Western Blot Analysis Cell Line:HCT 116 Concentration:5, 10, 20 μM Incubation Time:36 h Result:Inhibited the TNF (0.5 nM)-induced phosphorylation and nuclear translocation of p65.

Animal Model:HCT116 xenograft mouse model Dosage:40 mg/kg Administration:s.c., every 2-day. for 9 days Result:Inhibited colonic tumor growth completely at 9 days, with little effect on body weight.

——

Metabolic Enzyme/Protease

PPAR

Others

Cancer

——

524-17-4

624.77

C38H44N2O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (160.06 mM)

CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC)OC

——

(-20℃)

With Ice Pack

≥ 2 years